Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology

Navigating Relapsed MZL: Targeted Therapies and CAR T-Cell Therapy

At a Glance

If marginal zone lymphoma (MZL) relapses, patients have highly effective options like targeted daily pills (zanubrutinib) or one-time CAR T-cell therapies. Treatment choice depends on previous therapies, overall health, and preference for a daily pill versus an intensive hospital procedure.

Note: If you are newly diagnosed, reading about advanced therapies can be overwhelming. Keep in mind that many patients will not need these treatments for years or even decades, if ever. This information is here so you know that if the time comes, powerful options are available.

If your Marginal Zone Lymphoma (MZL) has returned or did not respond to your first treatment, it is important to know that there are now more “tools in the toolbox” than ever before. Because MZL is often slow-growing, a relapse is usually not an emergency, and there is time to carefully evaluate the next best step for your specific situation [1][2]. The landscape for relapsed MZL has shifted toward targeted therapies—drugs that home in on specific pathways in the cancer cells—and immunotherapies that reprogram your own immune system to fight the lymphoma [3][4].

BTK Inhibitors: A Daily Pill Approach

Bruton’s Tyrosine Kinase (BTK) inhibitors are oral medications that block a protein (BTK) that B-cells need to survive and grow [5].

  • Ibrutinib (The First Generation): Ibrutinib was the first BTK inhibitor used for MZL. While effective, it can sometimes affect other proteins in the body, leading to side effects like heart rhythm issues (atrial fibrillation), high blood pressure, or increased bleeding risk [6][7].
  • Zanubrutinib (The Second Generation): This newer drug is “more selective,” meaning it stays focused on the BTK protein and hits fewer “off-target” proteins. In studies, zanubrutinib has shown high response rates (around 68%) with a significantly lower risk of heart-related side effects compared to ibrutinib [3][8].

The Shift Away from PI3K Inhibitors

You may hear about a class of drugs called PI3K inhibitors (such as umbralisib or copanlisib). While these drugs can be effective, many have been withdrawn or are now less favored by doctors [9][10].

  • The Problem: These drugs can cause “immune-mediated” side effects, where the immune system attacks healthy parts of the body. This can lead to severe diarrhea (colitis), liver inflammation (hepatotoxicity), or life-threatening infections [11][12].
  • The Consensus: In many cases, the risks of these side effects outweigh the benefits for an indolent disease like MZL, especially when safer options like zanubrutinib are available [9].

CAR T-Cell Therapy: A Powerful One-Time Treatment

For patients whose disease has relapsed after several other treatments, CAR T-cell therapy offers a revolutionary approach. Doctors “train” your own T-cells (a type of immune cell) to recognize and kill the lymphoma [4][13].

  • Axicabtagene Ciloleucel (ZUMA-5 Trial): In a major study, this therapy showed an overall response rate of 77% in heavily pretreated MZL patients [4]. Many of these patients remained in remission for years after just a single infusion [4].
  • Lisocabtagene Maraleucel: Another CAR T option has shown even higher response rates (up to 95%) [13].
  • The Trade-off: CAR T is a complex process. It requires a stay at a specialized hospital because it can cause Cytokine Release Syndrome (CRS)—an intense immune reaction—or neurological issues. While these side effects can be severe or even life-threatening, specialized care teams are trained to monitor for and manage them closely [14][13].

Other Effective Options

If BTK inhibitors or CAR T are not the right fit, other strategies remain:

  • Lenalidomide + Rituximab (The “R2” Regimen): This combination uses an immune-modulating drug (lenalidomide) to help rituximab work better. It is often very effective for relapsed indolent lymphomas and is given in cycles over several months [15][16].
  • Clinical Trials: Many new “next-generation” drugs, such as pirtobrutinib, are currently being studied and offer hope for patients whose disease has even become resistant to other BTK inhibitors [17][18].

Choosing between these options depends on your overall health, your previous treatments, and whether you prefer the convenience of a daily pill or the high-intensity, one-time nature of CAR T-cell therapy [19][20].

Common questions in this guide

What are BTK inhibitors, and how do they treat relapsed MZL?
BTK inhibitors are daily oral medications that block a specific protein B-cells need to survive. Second-generation options like zanubrutinib are highly effective for relapsed MZL and have a significantly lower risk of heart-related side effects compared to older versions.
Why are PI3K inhibitors no longer recommended for MZL?
PI3K inhibitors can cause severe immune-mediated side effects, such as dangerous diarrhea, liver inflammation, or life-threatening infections. Doctors now generally prefer safer alternatives, like targeted BTK inhibitors, whose benefits outweigh the risks for a slow-growing disease like MZL.
What is CAR T-cell therapy for marginal zone lymphoma?
CAR T-cell therapy is a one-time treatment where your own immune cells are collected, modified to recognize and attack lymphoma cells, and then infused back into your body. It is highly effective for heavily pretreated MZL but requires a hospital stay to monitor for intense immune reactions.
What are the risks of CAR T-cell therapy?
The main risks include Cytokine Release Syndrome (CRS)—a severe immune reaction—and potential neurological issues. Because these side effects can be serious or life-threatening, the treatment is given at specialized centers where care teams can closely monitor and manage them.
What is the R2 regimen?
The R2 regimen combines lenalidomide, an immune-modulating daily pill, with rituximab infusions. This combination helps your immune system better target and destroy the lymphoma cells and is typically given in cycles over several months.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for a second-generation BTK inhibitor like zanubrutinib, and how does its safety profile compare to ibrutinib for someone with my health history?
  2. 2.What is the status of PI3K inhibitors in my treatment plan? Are there safer alternatives that avoid the risks of severe infection or colitis?
  3. 3.Given my previous treatments, would I be eligible for CAR T-cell therapy like axicabtagene ciloleucel or lisocabtagene maraleucel?
  4. 4.What are the specific risks of cytokine release syndrome (CRS) or neurological events if I choose CAR T-cell therapy, and how are these managed?
  5. 5.Would a combination like lenalidomide and rituximab (R2) be a better option for me than a single-agent targeted pill?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.

    Noor WD, Seymour JF, Cheah CY

    American journal of hematology 2026; (101(6)):1320-1340 doi:10.1002/ajh.70289.

    PMID: 41867085
  2. 2

    Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

    Junlén HR, Sonnevi K, Lindén O, et al.

    EJHaem 2023; (4(3)):647-655 doi:10.1002/jha2.696.

    PMID: 37601869
  3. 3

    Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.

    Phillips T, Chan H, Tam CS, et al.

    Blood advances 2022; (6(11)):3472-3479 doi:10.1182/bloodadvances.2021006083.

    PMID: 35390135
  4. 4

    Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

    Neelapu SS, Chavez JC, Sehgal AR, et al.

    Blood 2024; (143(6)):496-506 doi:10.1182/blood.2023021243.

    PMID: 37879047
  5. 5

    Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.

    Tam CS, Trotman J, Opat S, et al.

    Blood advances 2023; (7(12)):2884-2887 doi:10.1182/bloodadvances.2022008990.

    PMID: 36753605
  6. 6

    Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

    Gordon MJ, Feng L, Strati P, et al.

    Cancer 2024; (130(6)):876-885 doi:10.1002/cncr.35114.

    PMID: 37985359
  7. 7

    Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study.

    Ito A, Ito K, Iriyama C, et al.

    Cureus 2025; (17(10)):e95858 doi:10.7759/cureus.95858.

    PMID: 41181769
  8. 8

    Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

    Opat S, Tedeschi A, Hu B, et al.

    Blood advances 2023; (7(22)):6801-6811 doi:10.1182/bloodadvances.2023010668.

    PMID: 37682792
  9. 9

    PI3K Inhibitors in Hematology: When One Door Closes….

    Skånland SS, Okkenhaug K, Davids MS

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(17)):3667-3675 doi:10.1158/1078-0432.CCR-24-0967.

    PMID: 38967552
  10. 10

    Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.

    Munoz J, Follows GA, Nastoupil LJ

    Targeted oncology 2021; (16(3)):295-308 doi:10.1007/s11523-021-00802-9.

    PMID: 33687623
  11. 11

    Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis.

    Zhang Y, Ma Z, Wang Y, et al.

    Expert review of clinical pharmacology 2023; (16(9)):855-863 doi:10.1080/17512433.2023.2238602.

    PMID: 37489925
  12. 12

    Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia.

    Faehling S, Coelho M, Floerchinger A, et al.

    HemaSphere 2023; (7(3)):e840 doi:10.1097/HS9.0000000000000840.

    PMID: 36844182
  13. 13

    Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.

    Palomba ML, Schuster SJ, Karmali R, et al.

    Lancet (London, England) 2026; (407(10532)):963-975 doi:10.1016/S0140-6736(25)02435-3.

    PMID: 41692020
  14. 14

    Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

    Jacobson CA, Chavez JC, Sehgal AR, et al.

    The Lancet. Oncology 2022; (23(1)):91-103 doi:10.1016/S1470-2045(21)00591-X.

    PMID: 34895487
  15. 15

    AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

    Leonard JP, Trneny M, Izutsu K, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(14)):1188-1199 doi:10.1200/JCO.19.00010.

    PMID: 30897038
  16. 16

    NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.

    Vo DN, Alexia C, Allende-Vega N, et al.

    Oncoimmunology 2018; (7(4)):e1409322 doi:10.1080/2162402X.2017.1409322.

    PMID: 29632722
  17. 17

    Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

    Patel K, Vose JM, Nasta SD, et al.

    Blood advances 2026; (10(7)):2441-2451 doi:10.1182/bloodadvances.2025017489.

    PMID: 41544219
  18. 18

    The potential of pirtobrutinib in multiple B-cell malignancies.

    Jensen JL, Mato AR, Pena C, et al.

    Therapeutic advances in hematology 2022; (13()):20406207221101697 doi:10.1177/20406207221101697.

    PMID: 35747462
  19. 19

    Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.

    Bakker M, Kuipers MT, Kersten MJ, et al.

    Current opinion in oncology 2025; (37(5)):393-400 doi:10.1097/CCO.0000000000001160.

    PMID: 40511598
  20. 20

    Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review.

    Rivero A, Mozas P, Magnano L, López-Guillermo A

    Frontiers in oncology 2023; (13()):1170394 doi:10.3389/fonc.2023.1170394.

    PMID: 37207160

This page provides information on advanced and relapsed MZL treatments for educational purposes only. Always consult your hematologist or oncologist to determine the safest and most effective treatment plan for your specific situation.

Get notified when new evidence is published on Marginal zone lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.